Mid-term efficacy of beraprost, an oral prostacyclin analog, in the treatment of distal CTEPH: a case control study

Cardiology
Carmine Dario VizzaFrancesco Fedele

Abstract

Prostanoids are a well-established therapy for pulmonary arterial hypertension (PAH), and observational studies suggest their efficacy even in chronic thromboembolic pulmonary hypertension (CTEPH) patients. To compare the effects of 6 months of treatment with beraprost, an orally-active prostacyclin analog, in patients with distal CTEPH and PAH. Case-control study. Sixteen patients with severe pulmonary hypertension (NYHA II-IV), eight with distal CTEPH matched with eight patients with idiopathic PAH for similar effort tolerance. All patients were in stable clinical and hemodynamic condition for 3 months with maximal standard therapy. During the titration phase (4 weeks) beraprost was increased to maximal tolerated dose (mean daily dosage: CTEPH 275 +/- 47 microg, PAH 277 +/- 47 microg) in adjunction of standard therapy, patients were followed-up for 6 months. World Heart Organization (WHO) functional class, exercise capacity measured by distance walked in 6 min, and systolic pulmonary pressure (echocardiography), were evaluated at baseline, and at 1-, 3- and 6-month interval. At 6 months WHO class decreased significantly in both groups (CTEPH from 2.7 +/- 0.6 to 2.0 +/- 0.24, p < 0.05; PAH from 3.0 +/- 0.26 to 2.1 +/- 0.25, p ...Continue Reading

References

Aug 1, 1987·Annals of Internal Medicine·S RichS K Koerner
Jan 1, 1985·Journal of Chronic Diseases·G H GuyattS O Pugsley
Oct 1, 1984·Circulation·P J Cannon
May 3, 2002·Journal of the American College of Cardiology·Nazzareno GalièUNKNOWN Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group
Jul 4, 2002·Thorax·M C ZoiaUNKNOWN Pavia Thromboendarterectomy Group
Aug 2, 2002·The New England Journal of Medicine·Horst OlschewskiUNKNOWN Aerosolized Iloprost Randomized Study Group
Sep 3, 2002·Journal of the American College of Cardiology·Olivier SitbonGérald Simonneau
Jun 25, 2003·Journal of the American College of Cardiology·Robyn J BarstUNKNOWN Beraprost Study Group

❮ Previous
Next ❯

Citations

Jan 28, 2011·The New England Journal of Medicine·Gregory Piazza, Samuel Z Goldhaber
Sep 15, 2015·Expert Review of Respiratory Medicine·Charaka Hadinnapola, Joanna Pepke-Zaba
Nov 5, 2010·Clinics in Chest Medicine·William R AugerTerence K Trow
Mar 7, 2007·Clinics in Chest Medicine·Wayne L Strauss, Jeffrey D Edelman
Jan 16, 2007·Respiratory Medicine·S A van WolferenA Vonk Noordegraaf
Feb 24, 2009·Respiratory Medicine·Nabil SaoutiAnton Vonk Noordegraaf
Mar 15, 2014·Anesthesiology·Vikram ShenoySloan C Youngblood
Aug 30, 2016·Annals of the American Thoracic Society·Joanna Pepke-ZabaRichard Channick
May 3, 2019·Heart Failure Reviews·Yi ZhangZhihong Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Related Papers

American Journal of Respiratory and Critical Care Medicine
R CondliffeJ Pepke-Zaba
Journal of Thrombosis and Haemostasis : JTH
Nika Skoro-SajerIrene M Lang
© 2022 Meta ULC. All rights reserved